Compare TSE & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSE | ELUT |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 23.3M |
| IPO Year | 2014 | 2020 |
| Metric | TSE | ELUT |
|---|---|---|
| Price | $0.46 | $1.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.6M | 453.8K |
| Earning Date | 02-11-2026 | 03-05-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,133,800,000.00 | $21,746,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.44 | $0.50 |
| 52 Week High | $5.99 | $3.46 |
| Indicator | TSE | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 72.78 |
| Support Level | $0.44 | $0.74 |
| Resistance Level | $0.95 | $0.91 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 3.86 | 88.84 |
Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.